Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy

Experimental Eye Research

Volumn 122, Issue , 2014, Pages 123-131

  Wisniewska Kruk, Joanna ^a   Klaassen, Ingeborg ^a   Vogels, Ilse M C ^a   Magno, Aaron L ^c   Lai, Chooi May ^d   Van Noorden, Cornelis J F ^a   Schlingemann, Reinier O ^a,b   Rakoczy, Elizabeth P ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c LIONS EYE INSTITUTE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Akimba; Blood retinal barrier; BRB; Diabetic macular edema; Diabetic retinopathy; Mouse models; PLVAP; Retina

Indexed keywords

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GENE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PERICYTE; PERMEABILITY BARRIER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETINA FLUORESCEIN ANGIOGRAPHY; TRANSCYTOSIS; WILD TYPE;

AKIMBA; BLOOD-RETINAL BARRIER; BRB; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; MOUSE MODELS; PLVAP; RETINA;

ANGIOGENIC PROTEINS; ANIMALS; ANTIGENS, CD31; ANTIGENS, CD34; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CARRIER PROTEINS; CHEMOKINES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; GENE EXPRESSION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACULAR EDEMA; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; PERICYTES; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VON WILLEBRAND FACTOR;

EID: 84898680582     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.03.005     Document Type: Article

References (51)

1. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
2. Andersen C.L., Jensen J.L., Ørntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245-5250.
3. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Penn State Retina Research Group. Diabetes 1998, 47:1953-1960.
4. Armulik A., Genové G., Mäe M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., Johansson B.R., Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
5. Akita mouse as a model of early retinal complications in diabetes. Investig. Ophthalmol. Vis. Sci. 2005, 46:2210-2218.
6. Biallosterski C., Van Velthoven M.E.J., Michels R.P.J., Schlingemann R.O., DeVries J.H., Verbraak F.D. Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. Br. J. Ophthalmol. 2007, 91:1135-1138.
7. Carson-Walter E.B., Hampton J., Shue E., Geynisman D.M., Pillai P.K., Sathanoori R., Madden S.L., Hamilton R.L., Walter K.A. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin. Cancer Res. 2005, 11:7643-7650.
8. Cohen-Kashi Malina K., Cooper I., Teichberg V.I. Closing the gap between the in-vivo and in-vitro blood-brain barrier tightness. Brain Res. 2009, 1284:12-21.
9. Del Toro R., Prahst C., Mathivet T., Siegfried G., Kaminker J.S., Larrivee B., Breant C., Durate A., Takakura N., Fukamizu A., Penninger J., Eichmann A. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010, 116:4025-4033.
10. Erickson K.K., Sundstrom J.M., Antonetti D.A. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007, 10:103-117.
11. Feng Y., Venema V.J., Venema R.C., Tsai N., Behzadian M.A., Caldwell R.B. VEGF-induced permeability increase is mediated by caveolae. Investig. Ophthalmol. Vis. Sci. 1999, 40:157-167.
12. Gesuete R., Orsini F., Zanier E.R., Albani D., Deli M.A., Bazzoni G., De Simoni M.-G. Glial cells drive preconditioning-induced blood-brain barrier protection. Stroke 2011, 42:1445-1453.
13. Hammes H.-P., Lin J., Renner O., Shani M., Lundqvist A., Betsholtz C., Brownlee M., Deutsh U. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002, 51:3107-3112.
14. Hammes H.-P., Feng Y., Pfister F., Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011, 60:9-16.
15. Han Z., Guo J., Conley S.M., Naash M.I. Retinal angiogenesis in the Ins2 (Akita) mouse model of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54:574-584.
16. Hofman P., Blaauwgeers H.G.T., Tolentino M.J., Adamis A.P., Nunes Cardozo B.J., Vrensen G.F.J.M., Schlingemann R.O. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium invivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Curr. Eye Res. 2000, 21:637-645.
17. Hofman P., Blaauwgeers H.G.T., Vrensen G.F.J.M., Schlingemann R.O. Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. Ophthalmic Res. 2001, 33:156-162.
18. Hofman P., Van Blijswijk B.C., Gaillard P.J., Vrensen G.F.J.M., Schlingemann R.O. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch. Opthalmol. 2001, 119:861-866.
19. Huang H., Gandhi J.K., Zhong X., Wei Y., Gong J., Duh E.J., Vinores S.A. TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Investig. Ophthalmol. Vis. Sci. 2011, 52:1336-1344.
20. Akita diabetic mice. Investig. Ophthalmol. Vis. Sci. 2013, 54:854-863.
21. Klaassen I., Hughes J.M., Vogels I.M.C., Schalkwijk C.G., Van Noorden C.J.F., Schlingemann R.O. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Exp. Eye Res. 2009, 89:4-15.
22. Klaassen I., Van Noorden C.J.F., Schlingemann R.O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog. Retin. Eye Res. 2013, 34:19-48.
23. Kowluru R.A., Jirousek M.R., Stramm L., Farid N., Engerman R.L., Kern T.S. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 1998, 47:464-469.
24. Lai C.-M., Shen W.-Y., Brankov M., Lai Y.K.Y., Barnett N.L., Lee S.Y.S., Yeo I.Y., Mathur R., Ho J.E.S., Pineda P., Barathi A., Ang C.-L., Canstable I.J., Rakoczy E.P. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. 2005, 12:659-668.
25. Lai C.-M., Estcourt M.J., Wikstrom M., Himbeck R.P., Barnett N.L., Brankov M., Tee L.B., Dunlop S.A., Degli-Esposti M.A., Rakoczy E.P. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Investig. Ophthalmol. Vis. Sci. 2009, 50:4279-4287.
26. Liebner S., Plate K.H. Differentiation of the brain vasculature: the answer came blowing by the Wnt. J.Angiogenesis Res. 2011, 2:1.
27. McLenachan S., Chen X., McMenamin P.G., Rakoczy E.P. Absence of clinical correlates of diabetic retinopathy in the Ins2 (Akita) retina. Clin. Exp. Ophthalmol. 2013, 41:582-592.
28. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., Tanaka K., Niwa M. Anew blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009, 54:253-263.
29. Nakagawa S., Deli M.A., Nakao S., Honda M., Hayashi K., Nakaoke R., Kataoka Y., Niwa M. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 2007, 27:687-694.
30. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J.Cell Biol. 2003, 161:653-660.
31. Paolinelli R., Corada M., Orsenigo F., Dejana E. The molecular basis of the blood brain barrier differentiation and maintenance. Is it still a mystery?. Pharmacol. Res. 2011, 63:165-171.
32. Pascariu M., Bendayan M., Ghitescu L. Correlated endothelial caveolin overexpression and increased transcytosis in experimental diabetes. J.Histochem. Cytochem. 2004, 52:65-76.
33. Pfister F., Feng Y., vom Hagen F., Hoffmann S., Molema G., Hillebrands J.-L., Shani M., Deutch U., Hammes H.-P. Anovel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 2008, 57:2495-2502.
34. Rakoczy E.P., Ali Rahman I.S., Binz N., Li C.-R., Vagaja N.N., de Pinho M., Lai C.M. Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am. J. Pathol. 2010, 177:2659-2670.
35. Schlingemann R.O., Witmer A.N. Treatment of retinal diseases with VEGF antagonists. Prog. Brain Res. 2009, 175:253-267.
36. Schlingemann R.O., Dingjan G.M., Emeis J.J., Blok J., Warnaar S.O., Ruiter D.J. Monoclonal antibody PAL-E specific for endothelium. Lab. Investig. 1985, 52:71-76.
37. Schlingemann R.O., Bots G.T.A.M., Van Duinen S.G., Ruiter D.J. Differential expression of endothelium-specific antigen PAL-E in vasculature of brain tumors and preexistent brain capillaries. Ann. N. Y. Acad. Sci. 1988, 529:111-114.
38. Schlingemann R.O., Hofman P., Andersson L., Troost D., Van der Gaag R. Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye. Ophthalmic Res. 1997, 29:130-138.
39. Schlingemann R.O., Hofman P., Vrensen G.F.J.M., Blaauwgeers H.G.T. Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. Diabetologia 1999, 42:596-602.
40. Shen W.-Y., Lai C.M., Graham C.E., Binz N., Lai Y.K.Y., Eade E., Guidolin D., Ribatti D., Dunlop S.A., Rakoczy P.E. Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia 2006, 49:1690-1701.
41. Shue E.H., Carson-Walter E.B., Liu Y., Winans B.N., Ali Z.S., Chen J., Walter K.A. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci. 2008, 26:29.
42. Siemerink M.J., Klaassen I., Vogels I.M.C., Griffioen A.W., Van Noorden C.J.F., Schlingemann R.O. CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis 2012, 15:151-163.
43. Stan R.V., Kubitza M., Palade G.E. PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13203-13207.
44. Strickland L.A., Jubb A.M., Hongo J.-A., Zhong F., Burwick J., Fu L., Frantz G.D., Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J.Pathol. 2005, 206:466-475.
45. Vagaja N.N., Chinnery H.R., Binz N., Kezic J.M., Rakoczy E.P., McMenamin P.G. Changes in murine hyalocytes are valuable early indicators of ocular disease. Investig. Ophthalmol. Vis. Sci. 2012, 53:1445-1451.
46. Van Eeden P.E., Tee L.B.G., Lukehurst S., Lai C.-M., Rakoczy E.P., Beazley L.D., Dunlop S.A. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Investig. Ophthalmol. Vis. Sci. 2006, 47:4638-4645.
47. Wang W., Dentler W.L., Borchardt R.T. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:434-440.
48. Wisniewska-Kruk J., Hoeben K.A., Vogels I.M.C., Gaillard P.J., Van Noorden C.J.F., Schlingemann R.O., Klaassen I. Anovel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Exp. Eye Res. 2012, 96:181-190.
49. Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Investig. Ophthalmol. Vis. Sci. 2002, 43:849-857.
50. Witmer A.N., Vrensen G.F.J.M., Van Noorden C.J.F., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
51. Witmer A.N., Van Blijswijk B.C., Van Noorden C.J.F., Vrensen G.F.J.M., Schlingemann R.O. Invivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J.Histochem. Cytochem. 2004, 52:39-52.